Inqor Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 21-05-2024
- Paid Up Capital ₹ 0.10 M
as on 21-05-2024
- Company Age 4 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
About Inqor Pharmaceuticals
The Company is engaged in the Home Appliances Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Syed Raza, Jabeen Shaik, Chilamathur Amreen, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397KA2020PTC137960
- Company No.
137960
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Sep 2020
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Inqor Pharmaceuticals Private Limited offer?
Inqor Pharmaceuticals Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant.
Who are the key members and board of directors at Inqor Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Syed Raza  | Additional Director | 17-May-2022 | Current |
| Jabeen Shaik | Director | 24-Mar-2021 | Current |
| Chilamathur Amreen | Director | 24-Mar-2021 | Current |
| Paidi Himabindu | Director | 17-Nov-2020 | Current |
Financial Performance of Inqor Pharmaceuticals.
Enhance accessibility to Inqor Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Inqor Pharmaceuticals?
Unlock access to Inqor Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Inqor Pharmaceuticals?
Inqor Pharmaceuticals has a workforce of 0 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Inqor Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Inqor Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
